Clinical trials: HCC - Hepatocellular Carcinoma
Hepatocellular Carcinoma Non-resectable
Radiotherapy + Sintilimab + Bevacizumab Biosimilar for uHCC With PVTT
This study was a prospective, single-arm, single-center, phase II exploratory clinical study. To investigate the efficacy and safety of radiotherapy combined with sintilimab and bevacizumab biosimilar in the treatment of…
- Trial name
- NCT05530785
- Testing
- radiotherapy combined with sintilimab and bevacizumab biosimilar
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Yongchang Zhang
Hepatocellular Carcinoma
The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study
Transarterial chemoembolization (TACE) is considered the gold standard for treating intermediate-stage hepatocellular carcinoma (HCC). However, any treatment guidelines do not specify the criteria for repeating TACE.
- Trial name
- NCT05121571
- Testing
- HAIC, Sorafenib
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Liver Cirrhosis
Study of Factors Predicting Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma (HCC)
Results of liver transplantation, the best theoretical treatment for HCC, are limited by tumor recurrence. In order to limit this risk Milan criteria was proposed in 1996.
- Conditions
- Hepatocellular Carcinoma, Liver Cirrhosis, Evidence of Liver Transplantation
- Trial name
- EFAPRE (NCT01198704)
- Testing
- search of factors predicting tumor recurrence
- Where
- France
- Volunteers
- 372 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma, Cirrhosis
Radiofrequency-assisted Hepatectomy on the Outcomes of HCC Patients With Cirrhosis
Surgical resection is the most effective treatment of primary and secondary liver tumors. Technical innovations have mainly focused on minimizing bleeding during transection of the hepatic parenchyma because excessive hemorrhage…
- Trial name
- NCT01992978
- Testing
- Radiofrequency-assisted Hepatectomy, Conventional Hepatectomy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Southwest Hospital, China
Hepatocellular Carcinoma Non-resectable
Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)
This is an Open-label, Multicenter, Phase II clinical trial to evaluate the efficacy and safety of Transcatheter arterial chemoembolization (TACE), Lenvatinib combination with Sintilimab (Triple Therapy) sequential radiotherapy…
- Trial name
- NCT06561399
- Testing
- TACE, Lenvatinib combination with Sintilimab sequential radiotherapy
- Where
- 4 sites in China
- Volunteers
- 28 people
- Sponsor
- Fujian Provincial Hospital
Hepatocellular Carcinoma (HCC)
Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
Advanced hepatocellular carcinoma (HCC) remains a major therapeutic challenge. Although targeted therapy combined with immune checkpoint inhibitors has improved clinical outcomes, the objective response rate and conversion…
- Trial name
- NCT07832006
- Testing
- Irreversible Electroporation, Lenvatinib, Sintilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shunda Du
Primary Liver Cancer
Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC)
Present imaging modalities for primary liver cancer (hepatocellular carcinoma or HCC) have several shortcomings. One important shortcoming is the time delay between successful treatment and radiological confirmation of this…
- Trial name
- NCT01116804
- Testing
- MRI of the liver before start of treatment, MRI after treatment, PET-scan before treatment start
- Where
- Belgium
- Volunteers
- 36 people
- Sponsor
- University Hospital, Ghent
Hepatocellular Carcinoma, Metastasis
Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies
The purpose of this study is to evaluate the clinical feasibility and short-term outcome of switching monopolar RFA using a separable cluster electrode in patients with primary and secondary liver malignancies.
- Conditions
- Hepatocellular Carcinoma, Metastasis, Cholangiocarcinoma
- Trial name
- NCT02683538
- Testing
- Separable cluster electrode (Octopus®)
- Where
- South Korea
- Volunteers
- 196 people
- Sponsor
- Seoul National University Hospital
Liver Cancer
Sho-Saiko-To Following Removal of Liver Cancer By Embolization in Treating Patients With Liver Cancer That Cannot Be Surgically Removed
RATIONALE: The Chinese herbal medicine Sho-saiko-to contains ingredients that may slow the growth of tumor cells and stimulate a person's immune system to help kill tumor cells.
- Trial name
- NCT00040898
- Testing
- Sho-saiko-to
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma
Treatment for Patients With Multiple Hepatocellular Carcinomas Based on the NDR Scoring System
The aim of this study is to establish a selection criteria of hepatectomy for patients with multiple hepatocellular carcinomas based on the NDR Scoring System
- Trial name
- NCT02525952
- Testing
- Hepatectomy, TACE
- Where
- 2 sites in China
- Volunteers
- 320 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma Non-resectable
Efficacy and Safety of Transarterial Therapies+Donafenib + Anti-PD-1 Antibody for uHCC: A Retrospective Real-world Study
This Retrospective Real-world study was designed to evaluate the clinical efficacy and safety of the Combination of transarterial therapies with donafenib plus Anti-PD-1 Antibody for Unresectable Hepatocellular Carcinoma.
- Trial name
- NCT05638438
- Testing
- transarterial therapies
- Volunteers
- 100 people
- Sponsor
- Zhujiang Hospital
Hepatocellular Carcinoma, Colorectal Cancer Liver Metastasis
The Safety, Efficacy, and Immune Response of Multimodal Thermal Therapy in the Treatment of Malignant Liver Tumors
Multimodal thermal therapy (MTT), as an initiative integration of cryotherapy and radiofrequency heating, has been applied to treat various solid tumors.
- Trial name
- NCT07159048
- Testing
- Multimodal Tumor Thermal Therapy System, Radiofrequency Ablation System or Microwave Ablation System
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
Safety Study of NK Cells From Sibship to Treat the Recurrence of HCC After Liver Transplantation
The purpose of this study is to explore the safety of NK cells from Sibship in patients with recurrent hepatocellular carcinoma after liver transplantation.
- Trial name
- NCT02399735
- Testing
- Low Dose NK cells ×4 times, Normal Dose NK cells ×4 times, Normal Dose NK cells ×8 times
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatocellular Carcinoma
Chemoembolization for Hepatocellular Carcinoma
The aim of the current study is to study the safety and effectiveness of TACE using a high dose of cisplatin for treatment of HCC.
- Trial name
- NCT02821533
- Testing
- TACE, Cisplatin
- Where
- Hong Kong
- Volunteers
- 24 people
- Sponsor
- Chinese University of Hong Kong
Hepatocellular Carcinoma (HCC)
Effect of Biejia-Ruangan Compound on Survival Rate and Recurrence Rate of Hepatocellular Carcinoma After Radical Treatment
This study plans to enroll 704 patients with a history of chronic hepatitis B who have undergone radical treatment for hepatocellular carcinoma.
- Trial name
- BRCSRRRHCCART (NCT06923176)
- Testing
- Biejia-Ruangan compound, Routine medical care
- Volunteers
- 704 people
- Sponsor
- Zhiyun Yang
Hepatic Carcinoma
Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver Function
The purpose of this study is to investigate the safety and efficacy of irreversible electroporation for unresectable Hepatic carcinoma in poor liver function, also Progress Free Survival (PFS) and Over Survival (OS) will be…
- Trial name
- NCT02352935
- Testing
- NanoKnife LEDC System
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Hepatocellular Carcinoma
Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma
This is a single-centre, open-label, dose escalation, Phase 1 study. The primary objective is to determine the highest dose of TG02 citrate that can safely be given to patients with advanced hepatocellular carcinoma.
- Trial name
- NCT03738111
- Testing
- TG02 Citrate
- Sponsor
- Lee's Pharmaceutical Limited
Hepatocellular Carcinoma
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
A clinical trial to compare the pharmacokinetics and bioequivalence of BR2008 with BR2008-1 in healthy volunteers
- Trial name
- NCT05068193
- Testing
- BR2008-1 (R), BR2008 (T)
- Where
- South Korea
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hepatocellular Carcinoma
A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-141 at varying dose levels and frequencies.
- Trial name
- NCT01733004
- Testing
- MM-141
- Where
- 4 sites in United States, France
- Volunteers
- 42 people
- Sponsor
- Merrimack Pharmaceuticals
Hepatocellular Carcinoma (HCC)
TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC
The safety, clinical efficacy and prognostic factors of transcatheter arterial chemoembolization (TACE) and/or hepatic artery infusion chemotherapy (HAIC) combined with targeted immunotherapy for primary hepatocellular carcinoma…
- Trial name
- NCT07658833
- Testing
- TACE (transarterial chemoembolization) combined with targeted/immunotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University